Cantitate/Preț
Produs

Digital Code of Life – How Bioinformatics is Revolutionizing Science, Medicine and Business

Autor G Moody
en Limba Engleză Hardback – 24 feb 2004
A behind-the-scenes look at the most lucrative discipline within biotechnology Bioinformatics represents a new area of opportunity for investors and industry participants. Companies are spending billions on the potentially lucrative products that will come from bioinformatics. This book looks at what companies like Merck, Glaxo SmithKline Beecham, and Celera, and hospitals are doing to maneuver themselves to leadership positions in this area. Filled with in-depth insights and surprising revelations, Digital Code of Life examines the personalities who have brought bioinformatics to life and explores the commercial applications and investment opportunities of the most lucrative discipline within genomics. Glyn Moody (London, UK) has published numerous articles in Wired magazine. He is the author of the critically acclaimed book Rebel Code.
Citește tot Restrânge

Preț: 30610 lei

Nou

Puncte Express: 459

Preț estimativ în valută:
5858 6162$ 4850£

Carte disponibilă

Livrare economică 24 decembrie 24 - 07 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780471327882
ISBN-10: 0471327883
Pagini: 400
Dimensiuni: 159 x 236 x 31 mm
Greutate: 0.59 kg
Editura: Wiley
Locul publicării:Hoboken, United States

Public țintă

Readers of Wired and Technology Review, business technology enthusiasts, investors and analysts interested in biotechnology, relevant professionals in pharmaceutical and healthcare industries.

Cuprins


Notă biografică

GLYN MOODY is the author of Rebel Code. His work following Linux and its creator Linus Torvalds has been highly acclaimed. Moody's writings have appeared in numerous publications including Wired magazine, The Economist, New Scientist, Financial Times, The Guardian, and The Daily Telegraph.

Descriere

A behind-the-scenes look at the most lucrative discipline within biotechnology Bioinformatics represents a new area of opportunity for investors and industry participants. Companies are spending billions on the potentially lucrative products that will come from bioinformatics.